Scripps Research said its experimental fentanyl vaccine cut brain fentanyl levels by about 70% in mice and kept breathing normal after doses that typically cause severe respiratory depression.
Over 8 weeks, the vaccine trained mice to produce antibodies against a broad molecular signature shared across fentanyl-related drugs, aiming to stop the drug in the bloodstream before it reaches the brain.
The antibodies also blocked variants including carfentanil, China White, acetylfentanyl and furanylfentanyl, while showing little binding to medical opioids such as morphine, oxycodone, remifentanil and alfentanil.
Researchers say that broader targeting could avoid the main weakness of current fentanyl-vaccine approaches, which often recognize only one exact drug structure as illicit chemists keep altering formulations.
A new vaccine blocks fentanyl in mice, but can this lab success overcome the daunting 90% failure rate for new drugs?
If a fentanyl vaccine becomes reality, could it create a false sense of security and unintentionally encourage riskier drug use?
Fentanyl Vaccine Enters Human Trials: A New Front in the Fight Against the Opioid Overdose Crisis
Overview
The opioid crisis, declared a public health emergency in 2017, has claimed over half a million lives and continues to evolve, with synthetic opioids like fentanyl now causing most fatalities. In response, Scripps Research developed a fentanyl vaccine, which entered Phase I human trials in the Netherlands in January 2026. These trials focus on safety and immune response, aiming to determine the vaccine’s potential to prevent fentanyl overdose. Supported by funding from the National Institute on Drug Abuse, this innovative approach reflects a broader effort to create upstream solutions and adapt prevention strategies to the shifting landscape of the opioid epidemic.